CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Qiagen is expanding its next-generation sequencing portfolio of nine GeneRead DNAseq panels to about 20 during the course of this year. Qiagen is leveraging its molecular content and assay portfolio to create these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays.
Qiagen’s current offering includes eight focused and curated NGS gene panels, for breast, colon, liver, lung, ovarian, prostate, gastric, and blood cancers, and each covers about 20 genes of interest. Qiagen also offers a comprehensive cancer panel covering 124 genes. The panels being launched focus on various cancers as well as new disease areas.
Qiagen is integrating access to the cloud-based Variant Analysis software, acquired with Ingenuity Systems early this year, to its gene panels, enabling customers to rapidly translate raw sequencing data into actionable results.
The company also recently launched a full range of sample and library preparation products for NGS. Qiagen’s products are for research use only.
Qiagen, 800-426-8157